Prelude Therapeutics (PRLD) Current Assets (2019 - 2026)

Prelude Therapeutics has disclosed Current Assets across 8 years of filings, most recently posting $84.6 million for Q1 2026.

• Current Assets for Q1 2026 came in at $84.6 million, down 17.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $84.6 million (down 17.39% YoY), and the FY2025 annual result was $105.7 million, down 22.23% from the prior year.
• Current Assets came in at $84.6 million for Q1 2026 at Prelude Therapeutics, down from $105.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $270.0 million in Q1 2022 to a low of $58.3 million in Q3 2025.
• The 5-year median for Current Assets is $182.7 million (2024), against an average of $174.4 million.
• Across the five-year window, Current Assets gained 17.18% in 2024 and plunged 62.7% in 2025, its largest moves.
• Prelude Therapeutics' Current Assets stood at $204.4 million in 2022, then grew by 15.27% to $235.6 million in 2023, then slumped by 42.32% to $135.9 million in 2024, then fell by 22.23% to $105.7 million in 2025, then declined by 19.96% to $84.6 million in 2026.
• The last three Current Assets figures came in at $84.6 million (Q1 2026), $105.7 million (Q4 2025), and $58.3 million (Q3 2025), per Business Quant data.